CompletedPhase 2NCT00499031
Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer
Studying Squamous cell carcinoma of the cervix uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gynecologic Oncology Group
- Principal Investigator
- Alessandro Santin, MDGynecologic Oncology Group
- Intervention
- Cetuximab(biological)
- Enrollment
- 38 target
- Eligibility
- 18 years · FEMALE
- Timeline
- 2007
Study locations (22)
- Colorado Gynecologic Oncology Group, Aurora, Colorado, United States
- The Hospital of Central Connecticut, New Britain, Connecticut, United States
- Decatur Memorial Hospital, Decatur, Illinois, United States
- Saint Vincent Hospital and Health Services, Indianapolis, Indiana, United States
- Singing River Hospital, Pascagoula, Mississippi, United States
- CoxHealth South Hospital, Springfield, Missouri, United States
- Island Gynecologic Oncology, Brightwaters, New York, United States
- Memorial Sloan-Kettering Cancer Center, New York, New York, United States
- Stony Brook University Medical Center, Stony Brook, New York, United States
- University of North Carolina, Chapel Hill, North Carolina, United States
- Carolinas Medical Center, Charlotte, North Carolina, United States
- Akron General Medical Center, Akron, Ohio, United States
- MetroHealth Medical Center, Cleveland, Ohio, United States
- Riverside Methodist Hospital, Columbus, Ohio, United States
- University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
- +7 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00499031 on ClinicalTrials.gov